AbbVie, announced that it has completed its acquisition of ImmunoGen. With the completion of the acquisition, ImmunoGen is now part of AbbVie.
"Together with ImmunoGen,...
Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...
CooperSurgical, a global leader in fertility and women's health, and Fulgent Genetics, Inc. , a technology-based company with a well-established clinical diagnostic business and...
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its AI-driven discovery platform, announced the appointment of oncologist and industry veteran Neil Josephson, M.D.,...
Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors announces the appointment of Sean A. MacDonald...
